METTL3 inhibition, achieved via genetic knockdown or selective inhibitors, affects HSC activation and fibrotic gene expression, supporting its role as a therapeutic target in AFB<sub>1</sub>-induced liver fibrosis. This evidence concerns the gene METTL3 and Hepatic fibrosis.